ConCallIQ
Go Pro

Gujarat Fluorochemicals FY24 Annual Earnings Summary

4 quarters covered · ₹4,281 Cr revenue · ₹435 Cr PAT · 22.0% average EBITDA margin.

Total annual revenue: ₹4,281 Cr
Annual PAT: ₹435 Cr
Average margin: 22.0%
Promise delivery: 0%

Quarter-by-quarter progression

QuarterRevenuePATMarginSentiment
Q1 FY24₹1,209 Cr₹201 Cr29.0%bearish
Q2 FY24₹947 Cr₹53 Cr17.0%bearish
Q3 FY24₹992 Cr₹80 Cr21.0%neutral
Q4 FY24₹1,133 Cr₹101 Cr21.0%neutral

Management promises made during the year

Battery chemicals commissioning in Q2 FY24

Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.

Q2 FY24
missed
H2 FY24 better than H1 FY24

Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.

Q3 FY24
missed
Battery chemical sampling to start shortly

Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.

Q3 FY24
missed

Risks flagged during the year

Q1 FY24 · high

Destocking may persist longer than expected, delaying volume ramp-up and capacity utilization.

Q1 FY24 · high

Excess Chinese capacity and slowdown in EV sector are pressuring PVDF prices and volumes.

Q2 FY24 · high

Continued price pressure from Chinese and Russian competitors in commodity PTFE grades may persist, impacting margins.

Q4 FY24 · high

Analyst raised concern about high net debt-to-EBITDA (1.8x) and INR 800 crore CapEx; management confirmed external funding process but no guarantee.

Q1 FY24 · medium

Weak summer in domestic and overseas markets impacted refrigerant sales; Q2 expected to be similar to Q1.

Q1 FY24 · medium

Approval processes for battery-grade PVDF and semiconductor-grade PFA are taking longer than expected.

Q2 FY24 · medium

US phase-out of R125 and circumvention issues have structurally impacted export volumes; recovery may be limited.

Q2 FY24 · medium

High-cost inventory led to gross margin compression; normalization may take another quarter.

Q2 FY24 · medium

Despite management's confidence, PFAS regulations in Europe and US could impact fluoropolymer demand if scope widens.

Q3 FY24 · medium

Legacy player inventory may take longer to deplete than expected, delaying volume recovery.

Q3 FY24 · medium

Specialty chemical segment remains under pressure due to dumping from China, with no near-term improvement expected.

Q3 FY24 · medium

Analyst raised concern about funding of EV CapEx and potential dilution; management deferred answer to separate EV call.

What changed through the year

G

Q1 FY24 · H2 FY24 improvement expected

Management expects business environment to pick up from Q3 onwards and normalize by end of FY24.

G

Q1 FY24 · CapEx of ₹1,500 crore may spill over

Planned CapEx for FY24 may not be fully incurred this year; some may spill into next fiscal.

G

Q1 FY24 · Battery chemicals commissioning in Q2 FY24

LiPF6 and electrolyte plants expected to come online by end of Q2 FY24, with meaningful revenue in FY25.

G

Q1 FY24 · EBITDA margin guidance of 28-33%

Management expects EBITDA margins to remain in the 28-33% range for the full year.

G

Q2 FY24 · FY25 revenue and profit to surpass FY23 levels

Management expects FY25 to be better than FY23, implying recovery to peak levels.

G

Q2 FY24 · 30% EBITDA margin target for FY25

Management reaffirms 30% EBITDA margin as normal run-rate, expecting to achieve it in FY25.

G

Q2 FY24 · H2 FY24 better than H1 FY24

Management expects gradual improvement in H2 due to destocking phasing out and legacy player exits.

G

Q2 FY24 · Battery chemical sampling to start shortly

Integrated LiPF6 and electrolyte plants are in advanced commissioning; customer sampling imminent.

G

Q3 FY24 · FY25 EBITDA at par with FY23

Management revised guidance: FY25 EBITDA will be at similar levels to FY23 (INR ~1,900 crore), not higher, with a possible quarter variance.

G

Q3 FY24 · CapEx for existing business at INR 500 crore in FY25

CapEx for non-EV business in FY25 will be around INR 500 crore, staggered from earlier plans.

G

Q3 FY24 · Fluoropolymer capacity ramp-up over next 4 quarters

New fluoropolymer capacity (1,800-1,900 TPM) will be utilized over the next four quarters as approvals and customer validations progress.

G

Q3 FY24 · Battery chemical revenue from H2 FY25

Revenue from battery chemicals (PVDF) expected to start from second half of FY25, with meaningful contribution from FY26.

G

Q4 FY24 · FY25 EBITDA to be similar to FY23 levels (~INR 1,800-1,900 crore)

Management expects EBITDA to recover to FY23 levels, driven by fluoropolymer volume growth and new capacity ramp-up.

G

Q4 FY24 · Battery chemical commercial sales from H2 FY25

LiPF6 plant commissioned; sampling and customer engagement underway. Revenue expected to start trickling in from second half of FY25.

G

Q4 FY24 · CapEx of INR 800 crore for battery chemicals in FY25

Funding to be raised externally; investment bankers appointed. CapEx plan remains on track.

G

Q4 FY24 · Fluoropolymer segment to see continuous growth in FY25

Green shoots visible; destocking phasing out. New capacities in FKM, PFA, PVDF, and micropowders to drive volume and value growth.